Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + pegylated interferon + ribavirin
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral (simeprevir, Ribavirin), Subcutaneous (pegylated Interferon)
01
Overview
**Simeprevir + pegylated interferon + ribavirin** is a combination antiviral regimen used for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults with compensated liver disease, including cirrhosis. Simeprevir is an oral, once-daily second-generation NS3/4A protease inhibitor that blocks the protease enzyme essential for HCV replication, while pegylated interferon is an immunomodulatory agent that stimulates the antiviral immune response, and ribavirin is a nucleoside analogue that further inhibits viral replication. This combination significantly improves sustained virologic response (SVR) rates relative to dual therapy, in both treatment-naïve and treatment-experienced patients[1][2][3][4].
- Brand names
- Galexos (for simeprevir)No unique brand name for the specific triple combination
- Other names
- simeprevir-based triple therapy
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on simeprevir + pegylated interferon + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + pegylated interferon + ribavirin.